-
Sector | Healthcare |
---|---|
Industry | Diagnostics & Research |
Exchange | LSE |
CurrencyCode | GBP |
ISIN | GB00BM8HZD43 |
Market Cap | 5M |
---|---|
Beta | 1.67 |
PE Ratio | None |
Target Price | 20 |
Dividend Yield | None |
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VRCI.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025